A stakeholder-driven approach to improve the informed consent process for palliative chemotherapy.

Author(s): Enzinger AC,  Wind JK,  Frank E,  McCleary NJ,  Porter L,  Cushing H,  Abbott C,  Cronin C,  Enzinger PC,  Meropol NJ,  Schrag D

Journal: Patient Educ Couns

Date: 2017 Aug

Major Program(s) or Research Group(s): NCORP

PubMed ID: 28359659

PMC ID: PMC5492511

Abstract: OBJECTIVE: Patients often anticipate cure from palliative chemotherapy. Better resources are needed to convey its risks and benefits. We describe the stakeholder-driven development and acceptability testing of a prototype video and companion booklet supporting informed consent (IC) for a common palliative chemotherapy regimen. METHODS: Our multidisciplinary team (researchers, advocates, clinicians) employed a multistep process of content development, production, critical evaluation, and iterative revisions. Patient/clinician stakeholders were engaged throughout using stakeholder advisory panels, featuring their voices within the intervention, conducting surveys and qualitative interviews. A national panel of 57 patient advocates, and 25 oncologists from nine US practices critiqued the intervention and rated its clarity, accuracy, balance, tone, and utility. Participants also reported satisfaction with existing chemotherapy IC materials. RESULTS: Few oncologists (5/25, 20%) or advocates (10/22, 45%) were satisfied with existing IC materials. In contrast, most rated our intervention highly, with 89-96% agreeing it would be useful and promote informed decisions. Patient voices were considered a key strength. Every oncologist indicated they would use the intervention regularly. CONCLUSION: Our intervention was acceptable to advocates and oncologists. A randomized trial is evaluating its impact on the chemotherapy IC process. PRACTICE IMPLICATIONS: Stakeholder-driven methods can be valuable for developing patient educational interventions.